TMEM106B and frontotemporal dementia: With participants with a C9orf72 repeat expansion already showing signs of neurodegeneration (e.g., gray matter loss) before symptom onset, we hypothesize that TMEM106B is able to modulate the resilience against developing clinical FTD during these early stages of disease.